MR spectroscopy of cerebral white matter in type 2 diabetes; no association with clinical variables and cognitive performance

Abstract

We conclude that disturbances in neuronal viability and cellular membrane status assessed by NAA/Cr, Cho/Cr, NAA/Cho ratios cannot explain cognitive decline in patients with DM2.

Metabolite Differences in the Lenticular Nucleus in Type 2 Diabetes Mellitus Shown by Proton MR Spectroscopy

“…In the study of Tiehuis et al, 19 HbA1c was found to have no significant effect on the metabolite ratios in the corona radiata. We did, however, find that the NAA/Cr ratio in the lenticular nuclei of patients with T2DM was negatively related to FBG and HbA1c, while Cho/Cr was positively related to these 2 variables.…”

Quantitative multivoxel proton MR spectroscopy study of brain metabolites in patients with amnestic mild cognitive impairment: a pilot study

“…Increased Cho resonance probably reflects increased membrane synthesis or phospholipid turnover. Even though we use a similar short TE, the inconsistent results in the literature [46,[49][50][51] on this point may depend not only on the differences in volumes and locations of VOIs but also on different scanning protocols (others used SVS, while we used MVS). Follow-up interviews in our study revealed the symptoms of four out of seven aMCI patients were getting worse without treatment, while the rest had alleviated the symptoms, compatible with decreased brain Cho level, after taking medicine, such as Exelon or Aricept (cholinesterase inhibitors).…”

Assessment of changes in brain metabolites in Indian patients with type-2 diabetes mellitus using proton magnetic resonance spectroscopy

“…They also found that HbA1C level was inversely correlated with NAA/Cr and Cho/Cr ratios in the frontal cortex and with Cho/Cr ratio in parietal white matter [17]. However, contrary to these studies, Tiehuis et al studied 72 patients with type-2 DM and 40 control subjects using 1H-MRS and reported no differences in NAA/Cr, Cho/Cr or NAA/Cho ratios between patients with type-2 DM and controls; and neither cognitive performance in patients with type-2 DM was correlated with any of these brain metabolites nor were the clinical variables [22]. Some authors have used 1 H-MRS to evaluate brain metabolites in type-2 diabetic patients with other co-morbidity such as depression and hypothyroidism and have reported variable results.…”